| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.66, 0.98] | | < 1 | | 58% | 2 studies (2/-) | 98.6 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.69 [0.57, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.76 [0.63, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
| DCR | 1.15 [0.79, 1.68] | | > 1 | | 0% | 1 study (1/-) | 76.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.32 [0.91, 1.90] | | > 1 | | 0% | 2 studies (2/-) | 93.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.86 [1.34, 6.10] | | < 1 | | 26% | 2 studies (2/-) | 0.3 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 2.48 [1.36, 4.51] | | < 1 | | 83% | 2 studies (2/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.68 [0.84, 3.36] | | < 1 | | 0% | 2 studies (2/-) | 7.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 97.13 [5.95, 1585.40] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 3.19 [2.19, 4.65] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 5.64 [3.80, 8.35] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 11.25 [6.30, 20.10] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 7.00 [0.86, 57.23] | | < 1 | | 0% | 1 study (1/-) | 3.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.98 [0.02, 49.62] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 5.81 [0.69, 49.23] | | < 1 | | 0% | 2 studies (2/-) | 5.4 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 52.70 [7.19, 385.99] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 32.40 [7.79, 134.72] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.33 [0.15, 12.01] | | < 1 | | 82% | 2 studies (2/-) | 39.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.14 [0.02, 0.77] | | < 1 | | 0% | 2 studies (2/-) | 98.8 % | low | not evaluable | high | non important | - |
| Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.99 [0.17, 5.73] | | < 1 | | 0% | 2 studies (2/-) | 50.5 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 2.00 [0.18, 22.13] | | < 1 | | 0% | 2 studies (2/-) | 28.7 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 3.03 [0.17, 53.71] | | < 1 | | 81% | 2 studies (2/-) | 22.7 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 5.55 [1.41, 21.79] | | < 1 | | 0% | 2 studies (2/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 2.86 [1.61, 5.08] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 2.94 [0.58, 14.91] | | < 1 | | 0% | 2 studies (2/-) | 9.7 % | low | not evaluable | high | non important | - |
| Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.38 [0.67, 2.86] | | < 1 | | 0% | 2 studies (2/-) | 19.0 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 4.97 [0.58, 42.77] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 7.90 [0.98, 63.82] | | < 1 | | 0% | 2 studies (2/-) | 2.7 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 3.79 [0.36, 39.89] | | < 1 | | 0% | 2 studies (2/-) | 13.6 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 6.71 [1.20, 37.51] | | < 1 | | 0% | 2 studies (2/-) | 1.5 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.26] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.70 [0.85, 3.42] | | < 1 | | 0% | 2 studies (2/-) | 6.7 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 1.00 [0.14, 7.12] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
